5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide | 1436382-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide
• 英文别名: 6-(3-Pyridylamino)-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide；5,8-dioxo-6-(pyridin-3-ylamino)naphthalene-1-sulfonamide
• CAS: 1436382-03-4
• 化学式: C₁₅H₁₁N₃O₄S
• 分子量: 329.336
• InChiKey: GSGMKINCHGAOPK-UHFFFAOYSA-N

物化性质

• 沸点：
  635.6±65.0 °C(Predicted)
• 密度：
  1.585±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  128
• 氢给体数：
  2
• 氢受体数：
  7

制备方法与用途

LY5是一种STAT3抑制剂，其IC50值为0.5μM。LY5能够诱导细胞凋亡并抑制STAT3的磷酸化。此外，在体内实验中，LY5表现出显著的抗肿瘤活性，并可用于癌症研究。

反应信息

• 作为产物：
  描述：

  1-萘磺酰胺 在 chromium(VI) oxide 、 copper(II) acetate monohydrate 作用下， 以 水 、 溶剂黄146 、 三氟乙酸 为溶剂， 反应 0.3h， 生成 5,8-dioxo-6-(pyridin-3-ylamino)-5,8-dihydronaphthalene-1-sulfonamide
  参考文献：
  名称：

  Regioselective one-pot C–N coupling of substituted naphthoquinones: selective intramolecular ring fusion of sulfonamides

  摘要：

  The first one-pot copper-catalyzed highly regioselective C - N bond formation between aryl/alkyl amines and sulfonamide-substituted naphthoquinones was accomplished. Facile chemoselective routes obtained diverse ring-opening 6-amino/anilino-naphthalen-dione-1-sulfonamides and ring-fused 6-amino/aniline5H-naphth[1,8-cd]isothiazol-5-one,1,1 -dioxides with great functional group tolerance. Regiochemistry was confirmed by 1D- and 2D-NMRs. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.11.041

文献信息

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020206424A1

  公开（公告）日：2020-10-08

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• [EN] STAT3 INHIBITORS AND THEIR ANTICANCER USE<br/>[FR] INHIBITEURS DE STAT3 ET LEUR UTILISATION ANTICANCÉREUSE
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2014028909A1

  公开（公告）日：2014-02-20

  In one aspect, the invention relates to substituted substituted 6-amino-5,8-dioxo-5,8- dihydronaphthalene- 1 -sulfonamide analogs and derivatives thereof, substituted 4-amino-5H- naphtho[l,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  在一个方面，该发明涉及替代的替代6-氨基-5,8-二氧化-5,8-二氢萘磺酰胺类似物及其衍生物，替代的4-氨基-5H-萘并[1,8-cd]异噻唑酮-5-酮1,1-二氧化物类似物及其衍生物，以及相关化合物，这些化合物可用作STAT蛋白活性的抑制剂；制备这些化合物的合成方法；包含这些化合物的药物组合物；以及使用这些化合物和组合物治疗与STAT蛋白活性功能障碍相关的细胞不受控制增殖的疾病的方法。本摘要旨在作为在特定领域进行搜索的扫描工具，并不旨在限制本发明。
• STAT3 INHIBITORS AND THEIR ANTICANCER USE
  申请人：Ohio State Innovation Foundation

  公开号：US20150232434A1

  公开（公告）日：2015-08-20

  In one aspect, the invention relates to substituted 6-amino-5,8-dioxo-5,8-dihydronaphthalene-1-sulfonamide analogs and derivatives thereof, substituted 4-amino-5H-naphtho[1,8-cd]isothiazol-5-one 1,1-dioxide analogs and derivatives thereof, and related compounds, which are useful as inhibitors of STAT protein activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with a STAT protein activity dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本发明涉及替代的6-氨基-5,8-二氧代-5,8-二氢萘酚-1-磺酰胺类似物及其衍生物，替代的4-氨基-5H-萘并[1,8-cd]异噻唑-5-酮1,1-二氧化物类似物及其衍生物以及相关化合物，它们可用作STAT蛋白活性的抑制剂；制备这些化合物的合成方法；包含这些化合物的制药组合物；以及使用这些化合物和组合物治疗与STAT蛋白活性功能障碍相关的细胞不受控制增殖紊乱的方法。本摘要旨在作为特定领域搜索的工具，不限制本发明。
• Single domain antibodies directed against human immunodeficiency virus
  申请人：SINGH BIOTECHNOLOGY, LLC

  公开号：US10195277B2

  公开（公告）日：2019-02-05

  This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.

  本发明提供了在不使用外源靶向序列或化学组合物的情况下治疗病症或疾病的组合物和方法。本发明涉及单域抗体（sdAbs）、蛋白质和多肽，它们包含针对导致病症或疾病的靶点的 sdAbs。本发明还包括编码 sdAbs、蛋白质和多肽的核酸，以及包含 sdAbs 的组合物。本发明包括将组合物、sdAbs 和编码 sdAbs 的核酸用于预防、治疗或诊断目的。
• Single domain antibodies directed against ebola virus VP24
  申请人：SINGH BIOTECHNOLOGY, LLC

  公开号：US10369223B2

  公开（公告）日：2019-08-06

  This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.

  本发明提供了在不使用外源靶向序列或化学组合物的情况下治疗病症或疾病的组合物和方法。本发明涉及单域抗体（sdAbs）、蛋白质和多肽，它们包含针对导致病症或疾病的靶点的 sdAbs。本发明还包括编码 sdAbs、蛋白质和多肽的核酸，以及包含 sdAbs 的组合物。本发明包括将组合物、sdAbs 和编码 sdAbs 的核酸用于预防、治疗或诊断目的。